CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 262 filers reported holding CLOVIS ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $43,000 | -56.6% | 36,350 | -33.8% | 0.00% | -66.7% |
Q2 2022 | $99,000 | -49.0% | 54,881 | -42.9% | 0.00% | -40.0% |
Q1 2022 | $194,000 | -35.8% | 96,059 | -13.9% | 0.01% | -28.6% |
Q4 2021 | $302,000 | -39.2% | 111,518 | 0.0% | 0.01% | -50.0% |
Q3 2021 | $497,000 | -33.2% | 111,518 | -13.1% | 0.01% | -41.7% |
Q2 2021 | $744,000 | +35.5% | 128,322 | +64.1% | 0.02% | +14.3% |
Q1 2021 | $549,000 | +65.4% | 78,202 | +13.1% | 0.02% | +75.0% |
Q4 2020 | $332,000 | -30.1% | 69,114 | -15.1% | 0.01% | -58.6% |
Q3 2020 | $475,000 | +139.9% | 81,398 | +161.7% | 0.03% | +81.2% |
Q1 2020 | $198,000 | -77.1% | 31,100 | -46.6% | 0.02% | -79.7% |
Q2 2019 | $866,000 | -30.3% | 58,241 | +16.4% | 0.08% | -34.2% |
Q1 2019 | $1,242,000 | -48.9% | 50,053 | +92.8% | 0.12% | -76.3% |
Q2 2017 | $2,431,000 | +198.3% | 25,967 | +102.9% | 0.51% | +232.9% |
Q1 2017 | $815,000 | +211.1% | 12,800 | +116.9% | 0.15% | +153.3% |
Q4 2016 | $262,000 | – | 5,900 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |